Wednesday , July 28 2021
Home / The Angry Bear / Covid 19 One Dose or Two IV

Covid 19 One Dose or Two IV

Summary:
Angrybearblog December 22,2020 “Eyeballing, the first shot looks 80-90% effective.” (Moderna) and “my guess is that the first shot was about 90% effective over this period.” (Pfizer). Angrybearblog December 24,2020 New England Journal of Medicine February 17 2021 We used documents submitted to the Food and Drug Administration2 to derive the vaccine efficacy beginning from 2 weeks after the first dose to before the second dose (Table 1). Even before the second dose, BNT162b2 was highly efficacious, with a vaccine efficacy of 92.6%, a finding similar to the first-dose efficacy of 92.1% reported for the mRNA-1273 vaccine (Moderna).3With such a highly protective first dose, the benefits derived from a scarce supply of vaccine could be

Topics:
Robert Waldmann considers the following as important:

This could be interesting, too:

Stavros Mavroudeas writes ΣΥΝΕΝΤΕΥΞΗ ΜΕ ΤΟΝ ΣΤΑΥΡΟ ΜΑΥΡΟΥΔΕΑ ΓΙΑ ΤΗΝ ΠΑΝΔΗΜΙΑ ΚΑΙ ΤΙΣ ΣΥΝΕΠΕΙΕΣ ΤΗΣ ΣΤΗΝ ΟΙΚΟΝΟΜΙΑ ΚΑΙ ΤΗΝ ΕΡΓΑΣΙΑ – Bollettino Culturale

Dan Crawford writes Open thread July 27, 2021

Stavros Mavroudeas writes INTERVIEW WITH STAVROS MAVROUDEAS ON THE PANDEMIC AND ITS CONSEQUENCES ON THE ECONOMY AND WORK – Bollettino Culturale

Stavros Mavroudeas writes INTERVISTA A STAVROS MAVROUDEAS SULLA PANDEMIA E LE SUE CONSEGUENZE SULL’ECONOMIA E IL LAVORO – Bollettino Culturale

Angrybearblog December 22,2020 “Eyeballing, the first shot looks 80-90% effective.” (Moderna) and “my guess is that the first shot was about 90% effective over this period.” (Pfizer).

Angrybearblog December 24,2020

New England Journal of Medicine February 17 2021

We used documents submitted to the Food and Drug Administration2 to derive the vaccine efficacy beginning from 2 weeks after the first dose to before the second dose (Table 1). Even before the second dose, BNT162b2 was highly efficacious, with a vaccine efficacy of 92.6%, a finding similar to the first-dose efficacy of 92.1% reported for the mRNA-1273 vaccine (Moderna).3

With such a highly protective first dose, the benefits derived from a scarce supply of vaccine could be maximized by deferring second doses until all priority group members are offered at least one dose.

You read it here first

Robert Waldmann
Robert J. Waldmann is a Professor of Economics at Univeristy of Rome “Tor Vergata” and received his PhD in Economics from Harvard University. Robert runs his personal blog and is an active contributor to Angrybear.

Leave a Reply

Your email address will not be published. Required fields are marked *